Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir

Journal of Infectious Diseases

Volumn 177, Issue 4, 1998, Pages 898-904

  Angel, Jonathan B ^a   Kumar, Ashok ^b   Parato, Karl ^b   Filion, Lionel G ^b   Diaz Mitoma, Francisco ^b   Daftarian, Pirouz ^b   Pham, Ba ^b   Sun, Eugene ^b   Leonard, John M ^b   William Cameron, D ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; RITONAVIR; SAQUINAVIR;

ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 17344369291     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515244     Document Type: Article

References (13)

1. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus - seropositive patients. J Clin Invest 1989;84:1892-9.
2. Miedema F, Petit AJC, Terpstra FG, et al. Immunological abnormalities in human immunodeficiency virus (HIV) - infected asymptomatic homosexual men. J Clin Invest 1988;82:1908-14.
3. Wahren B, Morfeldt-Mansson L, Biberfeld G, et al. Impaired specific cellular response lo HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med 1986; 315:393-4.
4. Krowka JF, Stiles DP, Jain S, et al. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest 1989; 83:1198-203.
5. + T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995;172:79-87.
6. Roos MTL, Miedema F, Koot M, et al. T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus - infected asymptomatic subjects. J Infect Dis 1995;171:531-6.
7. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type I and cytotoxic lymphocytes. Blood 1994;84:4008-27.
8. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992;13:198-200.
9. Zlotnik A, Moore KW. Interleukin 10. Cytokine 1991;3:366-71.
10. Chehimi J, Starr SE, Frank I, et al. Impaired interleukin 12 production in human immunodeficiency virus - infected patients. J Exp Med 1994; 179:1361-6.
11. Chougnet C, Wynn TA, Clerici M, et al. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis 1996;174:46-53.
12. Daftarian MP, Diaz-Mitoma F, Creery WD, Cameron W, Kumar A. Dysregulated production of interleukin-10 (IL-10) and IL-12 by peripheral blood lymphocytes from human immunodeficiency virus - infected individuals is associated with altered proliferative responses to recall antigens. Clin Diagn Lab Immun 1995;2:712-8.
13. Clerici M, Wynn TA, Berzofsky JA, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994;93:768-75.